Drug guidance
Tenofovir alafenamide for treating chronic hepatitis B infection
Condition
Infections
Liver
18 January 2021
Published on 18 Jan 2021
Last Updated on 18 Jan 2021
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended listing tenofovir alafenamide (TAF) on the Medication Assistance Fund (MAF) for treating chronic hepatitis B infection, due to unfavourable cost-effectiveness compared with tenofovir disoproxil fumarate (TDF) at the price proposed by the manufacturer.
Tenofovir alafenamide for treating chronic hepatitis B infection (18 Jan 2021) [PDF, 46 KB]